John Sperzel joined T2 Biosystems as President and Chief Executive Officer, as well as a member of our Board of Directors in January 2020. Prior to that, he served as President and CEO of Chembio Diagnostics, Inc. (NASDAQ: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, from 2014 through 2020. Under John’s leadership, Chembio established direct U.S. and international sales teams resulting in significant growth, entered collaborations with two major pharmaceutical companies to create additional revenue opportunities, and made commercial investments in Latin America and Southeast Asia. Before Chembio, John served as President and CEO of ITC Medical, a privately-held point-of-care diagnostics company owned by Warburg-Pincus. Previously, he held executive and commercial leadership positions at Axis-Shield (Abbott), Bayer Diagnostics (Siemens), Instrumentation Laboratory, and Boehringer Mannheim (Roche). John earned his Bachelor of Science in Business/Management from Plymouth State University.